NGM BIOPHARMACEUTICALS INC
NGM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NGM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2023.
Tracking 5 pipeline candidates · 9 clinical trials for NGM BIOPHARMACEUTICALS INC.
Run NGM BIOPHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NGM BIOPHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
19.2 months
D/E 0.14
Lead: Phase 2/Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is NGM BIOPHARMACEUTICALS INC's lead drug candidate?
NGM BIOPHARMACEUTICALS INC's most advanced tracked candidate is aldafermin (Phase 2/Phase 3) for Primary Sclerosing Cholangitis.
Who is the CEO of NGM BIOPHARMACEUTICALS INC?
William J. Rieflin is the chief executive officer of NGM BIOPHARMACEUTICALS INC (NGM).
What therapeutic areas does NGM BIOPHARMACEUTICALS INC focus on?
NGM BIOPHARMACEUTICALS INC develops therapies across Oncology, Ophthalmology, Infectious Disease, Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.